Danco Laboratories, the maker of mifepristone, filed an emergency petition with the Supreme Court on Saturday to block a decision from the New Orleans-based 5th U.S. Circuit Court of Appeals that had restricted mail-order access to the drug just one day earlier. The appellate ruling represents the most significant shift in abortion policy in the United States since the 2022 overturning of Roe v. Wade.
Danco Laboratories, which also serves as a defendant in the underlying lawsuit, sought to halt the appellate court's decision while legal appeals continue. The company argued that the ruling would "inject immediate confusion and upheaval into highly time-sensitive medical decisions," according to its court filing.
